<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36160">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02635828</url>
  </required_header>
  <id_info>
    <org_study_id>2008H0170</org_study_id>
    <nct_id>NCT02635828</nct_id>
  </id_info>
  <brief_title>Effectiveness of Triple Therapy With Palonosetron for PON Prophylaxis</brief_title>
  <official_title>Studying the Effectiveness of Triple Therapy With Palonosetron, Dexamethasone and Promethazine for Prevention of Post Operative Nausea and Vomiting in High Risk Patients Undergoing Neurological Surgery and General Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative nausea and vomiting (PONV) is a displeasing experience that distresses
      surgical patients during the first 24 hours after a surgical procedure. The incidence of
      postoperative nausea occurs in about 50%, the incidence of postoperative vomiting is about
      30%, and in high-risk patients, the PONV rate could be as high as 80%. Therefore, the study
      design of this single arm, non-randomized, pilot study assessed the efficacy and safety
      profile of a triple therapy combination with palonosetron, dexamethasone and promethazine to
      prevent PONV in patients undergoing craniotomies under general anesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At induction of anesthesia, a triple therapy of palonosetron 0.075 mg IV, dexamethasone 10
      mg IV and promethazine 25 mg IV was given as PONV prophylaxis. After surgery, subjects were
      transferred to the surgical intensive care unit (SICU) or post anesthesia care unit as
      clinically indicated. Ondansetron 4 mg IV was administered as primary rescue medication to
      subjects with PONV symptoms. PONV was assessed and collected every 24 hours for 5 days via
      direct interview and/or medical charts review.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of subjects reporting postoperative nausea and/or vomiting</measure>
    <time_frame>24 hours after end of surgery</time_frame>
    <description>Subjects will be asked if they experienced nausea or vomiting durign the first 24 hours after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of subjects significant QTc changes in the EKG</measure>
    <time_frame>24 and 120 hours/discharge after end of surgery</time_frame>
    <description>EKG will be taken at baseline (before surgery), 24 hours after the end of surgery and 120/discharge after the end of surgery</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Postoperative Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Triple therapy PONV prohylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At induction of anesthesia, a triple therapy of palonosetron 0.075 mg IV, dexamethasone 10 mg IV and promethazine 25 mg IV was given as PONV prophylaxis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palonosetron 0.075 mg IV</intervention_name>
    <description>At induction of anesthesia, palonosetron 0.075 mg IV was given as PONV prophylaxis.</description>
    <arm_group_label>Triple therapy PONV prohylaxis</arm_group_label>
    <other_name>Aloxi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 10 mg IV</intervention_name>
    <description>At induction of anesthesia, dexamethasone 10 mg IV was given as PONV prophylaxis.</description>
    <arm_group_label>Triple therapy PONV prohylaxis</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Promethazine 25 mg IV</intervention_name>
    <description>At induction of anesthesia, promethazine 25 mg was given as PONV prophylaxis.</description>
    <arm_group_label>Triple therapy PONV prohylaxis</arm_group_label>
    <other_name>Phenergan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients, 18 to 85 years of age, of any race or gender. With an American
             Society of Anesthesiologist (ASA) physical status of I to III who are scheduled to
             undergo neurological surgery requiring opening of the cranium and Dura matter under
             general anesthesia, at Ohio State University Medical Center and who consent in
             writing to participating in this study.

          -  Post operative hospitalization expected to last at least 72 hours.

          -  Subjects whose surgery is expected to require at least 1 hours of general anesthesia

          -  Subjects who have a negative serum or urine pregnancy test within 1 day of surgery or
             who have been surgically sterilized or are postmenopausal.

        Exclusion Criteria:

          -  Subjects who are prisoners, pregnant, mentally ill, under the age of 18 or over the
             age of 85, ASA classification of V, alcohol or drug abusers.

          -  Subjects with known hypersensitivity to any 5-HT3 antagonist, to any agent that is
             part of the anesthesia regimen, or to other medications to be administered under this
             protocol.

          -  Subjects who are breastfeeding.

          -  Subjects who have had retching/vomiting or moderate to severe nausea in the 24 hours
             prior to anesthesia or suffer chronic nausea and/or vomiting

          -  Subjects who have been treated with any drug or other treatment with anti-emetic
             efficacy within the last 24 hours prior to the start of treatment.

          -  Subjects who have participated in a clinical trial of an investigational drug within
             30 days prior to surgery.

          -  Subjects who are participating in any other clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto A Uribe, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>The Ohio State University Wexner Medical Center</affiliation>
  </overall_official>
  <results_reference>
    <citation>Macario A, Weinger M, Carney S, Kim A. Which clinical anesthesia outcomes are important to avoid? The perspective of patients. Anesth Analg. 1999 Sep;89(3):652-8.</citation>
    <PMID>10475299</PMID>
  </results_reference>
  <results_reference>
    <citation>Kovac AL. Prevention and treatment of postoperative nausea and vomiting. Drugs. 2000 Feb;59(2):213-43. Review.</citation>
    <PMID>10730546</PMID>
  </results_reference>
  <results_reference>
    <citation>Fabling JM, Gan TJ, El-Moalem HE, Warner DS, Borel CO. A randomized, double-blinded comparison of ondansetron, droperidol, and placebo for prevention of postoperative nausea and vomiting after supratentorial craniotomy. Anesth Analg. 2000 Aug;91(2):358-61.</citation>
    <PMID>10910848</PMID>
  </results_reference>
  <results_reference>
    <citation>Gan TJ, Meyer T, Apfel CC, Chung F, Davis PJ, Eubanks S, Kovac A, Philip BK, Sessler DI, Temo J, Tramèr MR, Watcha M; Department of Anesthesiology, Duke University Medical Center.. Consensus guidelines for managing postoperative nausea and vomiting. Anesth Analg. 2003 Jul;97(1):62-71, table of contents. Review.</citation>
    <PMID>12818945</PMID>
  </results_reference>
  <results_reference>
    <citation>Audibert G, Vial V. [Postoperative nausea and vomiting after neurosurgery (infratentorial and supratentorial surgery)]. Ann Fr Anesth Reanim. 2004 Apr;23(4):422-7. Review. French.</citation>
    <PMID>15120791</PMID>
  </results_reference>
  <results_reference>
    <citation>Manninen PH, Raman SK, Boyle K, el-Beheiry H. Early postoperative complications following neurosurgical procedures. Can J Anaesth. 1999 Jan;46(1):7-14.</citation>
    <PMID>10078396</PMID>
  </results_reference>
  <results_reference>
    <citation>Apfel CC, Läärä E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting: conclusions from cross-validations between two centers. Anesthesiology. 1999 Sep;91(3):693-700.</citation>
    <PMID>10485781</PMID>
  </results_reference>
  <results_reference>
    <citation>Sanger GJ, Andrews PL. Treatment of nausea and vomiting: gaps in our knowledge. Auton Neurosci. 2006 Oct 30;129(1-2):3-16. Epub 2006 Aug 24. Review.</citation>
    <PMID>16934536</PMID>
  </results_reference>
  <results_reference>
    <citation>Habib AS, Gan TJ. Combination therapy for postoperative nausea and vomiting - a more effective prophylaxis? Ambul Surg. 2001 Jul;9(2):59-71.</citation>
    <PMID>11454483</PMID>
  </results_reference>
  <results_reference>
    <citation>Ku CM, Ong BC. Postoperative nausea and vomiting: a review of current literature. Singapore Med J. 2003 Jul;44(7):366-74. Review.</citation>
    <PMID>14620731</PMID>
  </results_reference>
  <results_reference>
    <citation>Habib AS, El-Moalem HE, Gan TJ. The efficacy of the 5-HT3 receptor antagonists combined with droperidol for PONV prophylaxis is similar to their combination with dexamethasone. A meta-analysis of randomized controlled trials. Can J Anaesth. 2004 Apr;51(4):311-9.</citation>
    <PMID>15064259</PMID>
  </results_reference>
  <results_reference>
    <citation>Khalil S, Philbrook L, Rabb M, Wells L, Aves T, Villanueva G, Amhan M, Chuang AZ, Lemak NA. Ondansetron/promethazine combination or promethazine alone reduces nausea and vomiting after middle ear surgery. J Clin Anesth. 1999 Nov;11(7):596-600.</citation>
    <PMID>10624646</PMID>
  </results_reference>
  <results_reference>
    <citation>Board T, Board R. The role of 5-HT3 receptor antagonists in preventing postoperative nausea and vomiting. AORN J. 2006 Jan;83(1):209-16, 219-20. Review.</citation>
    <PMID>16528908</PMID>
  </results_reference>
  <results_reference>
    <citation>Siddiqui MA, Scott LJ. Palonosetron. Drugs. 2004;64(10):1125-32; discussion 1133-4. Review.</citation>
    <PMID>15139789</PMID>
  </results_reference>
  <results_reference>
    <citation>Rojas C, Stathis M, Thomas AG, Massuda EB, Alt J, Zhang J, Rubenstein E, Sebastiani S, Cantoreggi S, Snyder SH, Slusher B. Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg. 2008 Aug;107(2):469-78. doi: 10.1213/ane.0b013e318172fa74. Erratum in: Anesth Analg. 2008 Oct;107(4):1405. Massuda, Edward B [corrected to Massuda, Ed B]; Rubenstein, Ed [corrected to Rubenstein, Edward]..</citation>
    <PMID>18633025</PMID>
  </results_reference>
  <results_reference>
    <citation>Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003 Oct;14(10):1570-7.</citation>
    <PMID>14504060</PMID>
  </results_reference>
  <results_reference>
    <citation>Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, Bertoli LF, Yunus F, Morrica B, Lordick F, Macciocchi A. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 2006 Sep;17(9):1441-9. Epub 2006 Jun 9.</citation>
    <PMID>16766588</PMID>
  </results_reference>
  <results_reference>
    <citation>Candiotti KA, Kovac AL, Melson TI, Clerici G, Joo Gan T; Palonosetron 04-06 Study Group.. A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo for preventing postoperative nausea and vomiting. Anesth Analg. 2008 Aug;107(2):445-51. doi: 10.1213/ane.0b013e31817b5ebb.</citation>
    <PMID>18633022</PMID>
  </results_reference>
  <results_reference>
    <citation>Kovac AL, Eberhart L, Kotarski J, Clerici G, Apfel C; Palonosetron 04-07 Study Group.. A randomized, double-blind study to evaluate the efficacy and safety of three different doses of palonosetron versus placebo in preventing postoperative nausea and vomiting over a 72-hour period. Anesth Analg. 2008 Aug;107(2):439-44. doi: 10.1213/ane.0b013e31817abcd3.</citation>
    <PMID>18633021</PMID>
  </results_reference>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 16, 2015</lastchanged_date>
  <firstreceived_date>December 8, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Sergio Bergese</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Palonosetron</keyword>
  <keyword>Craniotomy</keyword>
  <keyword>Nausea</keyword>
  <keyword>Vomiting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Palonosetron</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
